|Description||Elafibranor is a dual PPARα/δ agonist. Elafibranor increases plasma HDL and expression of Acox1, a PPARα target gene, and decreases plasma triglycerides and total cholesterol in the liver of ApoE2-KI wild-type mice. Elafibranor is identified as a drug candidate for the treatment of cardiometabolic diseases such as diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).|
|B0084-074234||250 mg||$299||In stock|
|Brife Description||PPARα/δ agonist|
|Synonyms||Elafibranor; GFT505; GFT-505; GFT 505; 2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid|
|Application||potential treatment of cardiometabolic diseases|
BADGE is a PPARγ antagonist with selectivity over PPARδ and PPARα. It inhibits adipocyte differentiation, and induces apoptosis in cancer cells. BADGE also exhi...
BM152054, a thiazolidinedione, revealed to be potent PPARg-activators in transient transfection assays in vitro.
JW74 is a tankyrase-specific inhibitor. JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. At the molec...
Inolitazone is an orally bioavailable PAPR-gamma inhibitor with potential antineoplastic activity. Inolitazone binds to and activates peroxisome proliferation-a...
The Rs for the separations were 3.5 for balaglitazone enantiomers, 3.5 for pioglitazone enantiomers, and 3.7 for rosiglitazone. The squared correlation coeffici...
Arhalofenateis, also known as JNJ-39659100 and MBX102, as an uricosuric agent it is a selective, partial PPAR-γ agonist.
Clofibrate is a fibric acid derivative used in the treatment of hyperlipoproteinemia type III and severe hypertriglyceridemia.
Bezafibrate (marketed as Bezalip and various other brand names) is a fibrate drug used for the treatment of hyperlipidaemia. It helps to lower LDL cholesterol a...